FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Federal Register

New Info Collection Sought for Drug Compounding Guide

Federal Register notice: FDA seeks OMB approval for a new information collection entitled Guidance for Industry on Compounded Drug Products That Are E...

Human Drugs

New Tools Needed for Opioid Addiction Drugs

FDA and NIH officials make the case for research into biomarkers that can predict efficacy of new opioid-abuse drugs based on reducing the quantity a...

Human Drugs

Amgen Gains Expanded Approval for Blincyto

FDA grants Amgen accelerated approval for Blincyto (blinatumomab) and its expanded use to treat adults and children with B-cell precursor acute lympho...

Human Drugs

Insmed NDA for Alis in Lung Disease

Insmed files an NDA for Alis (amikacin liposome inhalation suspension), indicated for treating adult patients with nontuberculous mycobacterial lung d...

Human Drugs

OIG Calls for FDA Supply Chain Education

The HHS Inspector General says FDA should educate drug dispensers about their responsibilities under the Drug Supply Chain Security Act.

Medical Devices

Stakeholders Appreciate IVD Draft Guidance

Three industry stakeholders praise an FDA draft guidance on IVDs and suggest changes.

Medical Devices

FDA Approves Hologic PMA for Clarity HD Breast Imaging

FDA approves a Hologic PMA for its Clarity HD high-resolution 3D imaging and Intelligent 2D imaging technology and their use on the companys 3Dimensio...

Biologics

Bristol-Myers Squibb sBLA for Colorectal Cancer

FDA accepts for review a Bristol-Myers Squibb supplemental BLA for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for treating certain adu...

Human Drugs

Mixed Views on FDA Mifeprex Monitoring

The Government Accountability Office says that stakeholders have both positive and negative comments on FDA monitoring of the abortion drug Mifeprex a...

Federal Register

Gastrointestinal Drugs Advisory Committee Charter Extended

Federal Register notice: FDA renews for an additional two years the charter for its Gastrointestinal Drugs Advisory Committee.